Showing results (101-110 of 370) with videos related to
Sort By:
Pageof 37
Drugs & Aging|June 10, 2025
Real-World Harm Reduction of Metformin Plus DPP4 Inhibitors versus Metformin Plus Sulfonylureas in Older Adults: A Target Trial Emulation Using German Claims DataPaula Starke, Petra Thürmann, Thomas Grobe, et al.BMC Medical Research Methodology|July 14, 2016
EFSPI/PSI working group on data sharing: accessing and working with pharmaceutical clinical trial patient level datasets - a primer for academic researchersRebecca Sudlow, Janice Branson, Tim Friede, et al.Biometrical Journal. Biometrische Zeitschrift|November 26, 2016
Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptationsCornelia U Kunz, Nigel Stallard, Nicholas Parsons, et al.Statistics in Medicine|June 27, 2015
Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trialNigel Stallard, Cornelia Ursula Kunz, Susan Todd, et al.Neurology|September 28, 2005
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosisDavid J Rog, Turo J Nurmikko, Tim Friede, et al.Journal of Biopharmaceutical Statistics|April 5, 2014
A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpointsCornelia Ursula Kunz, Tim Friede, Nicholas Parsons, et al.Spine|November 8, 2012
Systematic review of randomized controlled trials of clinical prediction rules for physical therapy in low back painShilpa Patel, Tim Friede, Robert Froud, et al.Drug Design, Development and Therapy|June 1, 2011
Development of oral immunomodulatory agents in the management of multiple sclerosisRichard Nicholas, Paolo Giannetti, Ali Alsanousi, et al.The Clinical Journal of Pain|June 19, 2007
Validation and reliability of the Neuropathic Pain Scale (NPS) in multiple sclerosisDavid J Rog, Turo J Nurmikko, Tim Friede, et al.Pharmaceutical Statistics|May 3, 2014
Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome dataCornelia Ursula Kunz, Tim Friede, Nick Parsons, et al.Pageof 37